Assessment of Late Effects*
| Complication | Surveillance | Treatment Modality |
|---|---|---|
| Growth failure | History/examination | Chemotherapy |
| Cranial radiation | ||
| Intellectual function | Psychiatric test | Cranial radiation |
| Neurological toxicity | Neurologic examination | Cranial radiation |
| Vincristine | ||
| Dental | Examination | Chemotherapy |
| Cleaning | Cranial radiation | |
| Male infertility | LH, FSH | Abdominal/pelvic radiation |
| Testosterone | Cyclophosphamide | |
| Sperm count | Doxorubicin/daunomycin | |
| Female infertility | LH, FSH | Abdominal/pelvic radiation |
| Estradial | Cyclophosphamide | |
| Doxorubicin/daunomycin | ||
| Cardiac | ECG, echocardiogram | Doxorubicin/daunomycin |
| Bladder | Urinalysis | Cyclophosphamide |
| Ifosphamide | ||
| Lung | Chest radiograph | Buslfan |
| Liver | LFTs | Methotrexate |
| Bone | DEXA scan | Prednisone/dexamethasone |
| Methotrexate | ||
| Eye (cataracts) | Visual acuity | Prednisone/dexamethasone |
| Ear (hearing) | Audiogram | Cisplatinum/carboplatinum |
| Second neoplasms | Examination | Radiation |
| Blood count | Cyclophosphamide | |
| Urinalysis | Doxorubicin/daunomycin | |
| Recurrence | History/examination |
* As recommended in “Long-Term Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers,” published by the Children's Oncology Group in 2008 (www.survivorshipguidelines.org).
LH, luteinizing hormone; FSH, follicle-stimulating hormone; ECG, electrocardiogram; LFT, liver function test; DEXA, dual energy x-ray absorptiometry.